Intervet International, B.V. et al. vs Boehringer Ingelheim Vetmedica, Inc. et al.

Decision Denying Institution of Inter Partes Review

Petitioner's Updated Mandatory Notices

Petitioner's Updated Power of Attorney

Ex. 2102 - Ellis - Porcine Circovirus: A Historical Perspective

Exhibit 2106 - Excerpts of Prosecution History of U.S. Patent No. 8,025,888

Ex. 2109 - Jestin et al., U.S. Patent No. 7,223,594

Patent Owner Preliminary Response

Ex. 2101 - Allan - Novel porcine circoviruses from pigs with wasting disease syndromes

Ex. 2103 - Tucker - Porcine multi-systemic wasting syndrome (PMWS) a review

Ex. 2104 - Ramshaw - The prime-boost strategy: exciting prospects for improved vaccination

Ex. 2105 - Excerpt of Prosecution History of U.S. Patent Application No. 13/190,452

Ex. 2107 - Excerpts of Prosecution History of U.S. Patent No. 7,700,285

Ex. 2108 - Excerpts of Prosecution History of U.S. Patent No. 7,833,707

Ex. 2114 - Siebel - Part 2. Global experience from the field around one-shot vaccination

Ex. 2115 - Desrosiers - Preliminary results with Ingelvac CircoFLEX to protect multiple ages of Quebec pigs against PCVAD

Ex. 2110 - Jestin et al., U.S. Patent No. 7,223,407

Ex. 2111 - Jestin et al., U.S. Patent No. 7,951,907

Ex. 2112 - Petition for Inter Partes Review of U.S. Patent No. 9,011,872 in IPR2018-01788 (Sept. 24, 2018)

Ex. 2113 - Patent Owner¿¿¿s Preliminary Response to the Petition in IPR2018-00919 (July 24, 2018).

Ex. 2116 - Chevez - Long-term analysis of PCV2 prevalence in a Mexican herd using Ingelvac CircoFLEX

Ex. 2117 - M. Fenaux - Immunogenicity and Pathogenicity of Chimeric Infectious DNA Clones of Pathogenic Porcine Circovirus Type 2 (PCV2) and Nonpathogenic PCV1 in Weanling Pigs

Notice of Accord Filing Date

Patent Owner's Power of Attorney

Patent Owner Boehringer Ingelheim Vetmedica, Inc.'s Mandatory Notices Pursuant to 37 C.F.R. 42.8(a)(2)

Petitioner's Power of Attorney

Complaint in Boehringer Ingelheim Vetmedica, Inc. v. Merck & Co., Inc. and Intervet Inc. a/k/a Merck Animal Health, Case No. 2:18-cv-09534-JMV-JBC (D.N.J. May 21, 2018) (ECF No. 1)

Prosecution History of U.S. Patent No. 9,011,872 - Part 1

Eichmeyer et al., U.S. Patent No. 9,011,872 ("the '872 Patent")

Prosecution History of U.S. Patent No. 9,011,872 - Part 3

Meng et al., International Publication No. WO 2003/049703 (¿¿¿Meng¿¿¿)

M. Fenaux, T., et al., A Chimeric Porcine Circovirus (PCV), etc., 78 J.VIROL. 6297 (2004) (¿¿¿Fenaux¿¿¿)

Prosecution History of U.S. Patent No. 9,011,872 - Part 2

Jestin et al., U.S. Patent No. 6,703,023 ("Jestin")

Blanchard et al., ¿¿¿Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV-2) proteins,¿¿¿ VACCINE 21:4565-4575 (2003) (¿¿¿Blanchard¿¿¿)

Merial, Inc.¿¿¿s Petition for Inter Partes Review of US Patent No. 8,008,001 Under 35 U.S.C. ¿¿¿¿ 311-319 and 37 C.F.R. ¿¿ 42.1-.80 & 42.100-.123

Declaration of Merrill L. Schaeffer, Ph.D. and enclosures

Declaration of Darin Madson, D.V.M., Ph.D.

Parisot et al., International Publication No. WO 2005/009462 A2 (February 3, 2005) (¿¿¿Parisot¿¿¿)

D. Mahe, et al., Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes, 81 J. VIROL. 1815 (2000) (¿¿¿Mahe¿¿¿)

M. Fort, A. Olvera, M. Sibila, J. Segal¿¿s & E. Mateu, Direction of Neutralizing Antibodies in Postweaning Multisystemic Wasting Syndrome (PMWS)-Affected and Non-PMWS-Affected Pigs, Veterinary Microbiology 125, 244-255 (2007) (¿¿¿Fort¿¿¿)

G. Sala, et al., Development of Monocolonal Antibodies Based on ELISAs for the Detection of Antibodies, etc., The 5th International Congress of Veterinary Virology, Veterinary Virology in the New Millennium (2000) (¿¿¿Sala¿¿¿)

L. Truchan, R. Jolie, P. Runnels, & D. McGavin, Eighteen Week Duration of Immunity in Pigs Vaccinated at 3 or 8 Weeks of Age with One Dose of a Mycoplasma hyopneumoniae Bacterin, American Association of Swine Practitioners (2000) (¿¿¿Truchan¿¿¿)

John C.S. Harding & Edward G. Clark, Recognizing and diagnosing postweaning multisystemic wasting syndrome (PMWS), 5 SWINE HEALTH AND PRODUCTION 201 (1997) (¿¿¿Harding 1997¿¿¿)

G. M. Allan, et al., Isolation of porcine circovirus-like viruses from pigs with a wasting disease in the USA and Europe, 10 J. VET. DIAGN INVEST 3 (1998) (¿¿¿Allan 1998¿¿¿)

John C.S. Harding, The clinical expression and emergence of porcine circovirus 2, 98 VET. MICROBIOL. 131 (2004) (¿¿¿Harding 2004¿¿¿)

Joaquim Segales, Gordon M. Allan & Mariano Domingo, Porcine circovirus diseases, 6 ANIMAL HEALTH RES. REV. 119 (2005) (¿¿¿Segal¿¿s¿¿¿)

Roman M. Pogranichniy, Kyoung-Jin Yoon, Perry A. Harms, Sabrina L. Swenson, Jeffrey J. Zimmerman & Steven D. Sorden, Characterization of immune response of young pigs to porcine circovirus type 2 infection, 13 VIRAL IMMUNOL. 143 (2000) (¿¿¿Pogranichnyy¿¿¿)

A. Mankertz., J. Mankertz, K. Wolf & H.J. Buhk, Identification of a protein essential for replication of porcine circovirus, 79 J.GEN.VIROL. 381 (1998) (¿¿¿Mankertz 1998¿¿¿)

I. Brunborg, et al., Quantitation of porcine circovirus type 2 isolated from serum/plasma and tissue samples of healthy pigs and pigs with postweaning multisystemic wasting syndrome, etc., 122 J. VIROLOGICAL METHODS 171 (2004) (¿¿¿Brunborg¿¿¿)

Patrick Halbur & Tanja Opriessnig, Update on Porcine Circovirus Type 2 (PCV2)-Associated Diseases, VET. DIAGN. PRODUCTION ANIMAL MED. (¿¿¿Halbur¿¿¿)

Bublot et al., U.S. Patent No. 6,497,883 (¿¿¿Bublot¿¿¿)

Fenaux et al., ¿¿¿Genetic Characterization of Type 2 Porcine Circovirus (PCV-2), etc.,¿¿¿ Journal of Clinical Microbiology, 38:2494-2503 (2000) (¿¿¿Fenaux 2000¿¿¿)

G. Reynaud, S. B¿¿s¿¿me, A. Brun, C. Charreyre, S. Desgouilles, P. Jeannin & S. Rehbein, Safety of a High Dose Administration of an Inactivated Adjuvanted PCV2 Vaccine in Conventional Gilts, 1 PROCEEDINGS OF THE 18TH IPVS CONGRESS 87 (2004) (¿¿¿Reynaud¿¿¿)

Declaration of Christopher C. L. Chase

Porntippa Nawagitgul, Igor Morozov, Steven R. Bolin, Perry A. Harms, Steven D. Sorden & Prem S. Paul, Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein, 81 J.GEN.VIROL. 2281 (2000) (¿¿¿Nawagitgul¿¿¿)

H. Jorio, R. Tran & A. Kamen, Stability of Serum-Free and Purified Baculovirus Stocks Under Various Storage Conditions, Biotechnol Prog. 22, 319-325 (2006) (¿¿¿Jorio¿¿¿)

Y. Okuda, et al., Experimental Reproduction of Postweaning Multisystem Wasting Syndrome in Cesaren-deprived, Colostrum-deprived Piglets Inoculated with Porcine Circovirus Type 2 (PCV2), etc., 15 J. Vet. Diag. Invest 107-114 (2003) (¿¿¿Shibata¿¿¿).

Monique M. van Oers, Vaccines for Viral and Parasitic Diseases Produced with Baculovirus Vectors, 68 ADVANCES VIRUS RES. 193 (2006) (¿¿¿van Oers¿¿¿)

M. Roof, K. Burkhart, and F. Zuckermann, Evaluation of the Immune Response and Efficacy of 1 and 2 dose commercial Mycoplasma hyopneumoniae bacterins, AMERICAN ASSOCIATION OF SWINE VETERINARIANS (2000) (¿¿¿Roof¿¿¿)

A. Dawson, R. E. Harvey, S. J. Thevasagayam, J. Sherington, A. R. Peters, Studies of the Field Efficacy and Safety of a Single-Dose Mycoplasma hyopneumoniae Vaccine for Pigs, THE VETERINARY RECORD (Nov. 2, 2002) (¿¿¿Dawson¿¿¿)

Haemophilus Parasuis Bacterin Ingelvac HP-1 Product Label, Boehringer Ingelheim Vetmedica, Inc.

Product News, NATIONAL HOG FARMER (Dec. 15, 2003).

New Mycoplasma Vaccine Offers Convenience, Effective Protection, HIGH PLAINS/MIDWEST AG JOURNAL, (Feb. 14, 2005) http://www.hpj.com/archives/new-mycoplasma-vaccine-offers-convenience-effective-protection/article_aab328d5-1df1-590e-aed8-bc11330a46eb.html.

Erysipelothrix Rhusiopathiae-Haemophilus Parasuis Vaccine and Methods of Using the Same, International Publication No. WO 2005/041890 A2

M. Kiupel, G.W. Stevenson, S.K. Mittal, E.G. Clark & D.M. Haines, Circovirus-like Viral Associated Disease in Weaned Pigs in Indiana, 35 VET. PATHOL. 303 (1998) (¿¿¿Kiupel¿¿¿)

Yuna Kim, Jinhyun Kim, Kyoungsoo Kang & Young S. Lyoo, Characterization of the Recombinant Proteins of Porcine Circovirus Type2 Field Isolate Expressed in the Baculovirus System, 3 J. VET. SCI. 19 (2002) (¿¿¿Kim¿¿¿)

Annette Mankertz & Bernd Hillenbrand, Replication of porcine circovirus type 1 requires two proteins encoded by the viral rep gene, 279 VIROLOGY 429 (2001) (¿¿¿Mankertz 2001¿¿¿)

F. McNeilly, I. McNair, D. P. Mackie, B. M. Meehan, S. Kennedy1 D. Moffett, J. Ellis, S. Krakowka & G. M. Allan, Production, characterisation and applications of monoclonal antibodies to porcine circovirus 2, 146 ARCH VIROL 909 (2001) (¿¿¿McNeilly¿¿¿)

Gordon M. Allan & John A. Ellis, Porcine circoviruses: a review, 12 J. VET. DIAGN. INVEST. 3 (2000) (¿¿¿Allan 2000¿¿¿)

P. Rueda, J. Fominaya, J. Langeveld, C. Bruschke, C. Vela, & J. Casal, Effect of Different Baculovirus Inactivation Procedures on the Integrity and Immunogenicity of Porcine Parvovirus-like Particles, 19 Vaccine 726-734 (2001) (¿¿¿Rueda¿¿¿)

J. Carr & Garth Veterinary Group, Garth Pig Stockmanship Standards, THE PIG SITE, (Sept. 14, 2018, 2:45 p.m.) http://www.thepigsite.com/stockstds/17/growth-rate/. (¿¿¿Carr¿¿¿).

P. Offit & R. Jew, Adressing Parents¿¿¿ Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals? 112 Pediatrics 6 (December 2003) (¿¿¿Offit¿¿¿)

M. Kuhn, Comparative Safety Evaluation of a One-dose M.hyopneumoniae bacterin (¿¿¿RespiSure-One) and a Competitor One-dose M. hyopneumoniae bacterin, Pfizer Animal Health Swine Veterinary Services (¿¿¿Respisure One¿¿¿)

SIV Vaccine, dvm360 (Mar. 1, 2004), http://veterinarynews.dvm360.com/siv-vaccine

European Patent No. EP2281829

Application No. 10174465.4 Information regarding oral proceedings of 12.09.18

Chanhee Chae, Commercial porcine circovirus type 2 vaccines: Efficacy and clinical application, 194 Vet. J. 151 (2012) (¿¿¿Chae¿¿¿)

Ellis et al., U.S. Patent No. 6,517,843 (¿¿¿Ellis¿¿¿)

M. Mombarg, Is One More Than Two?, 34 IPVS Health Pig International 3 (March 2004) (¿¿¿Mombarg¿¿¿)

P.C. Liao, Y.L. Lin, M.H. Jong, & W.B. Chung, Efficacy of Foot-and-Mouth Disease Vaccine in Pigs with Single Dose Immunization, 21 Vaccine 1807-1810 (2003) ("Liao")

R. Moorman, A. Bouma, J. Kramps, C. Terpstra, H. De Smit, Development of a Classical Swine Fever Subunit Marker Vaccine and Companion Diagnostic Test ("Moorman")

B. Bosworth, Evaluation of a One-dose Mycoplasma hyopneumoniae Bacterin and a One-dose Erysipelas Rhusiopathie Bacterin, American Association of Swine Veterinarians (2004) ("Pneumonostar Myco _ Panstar Ery")

M. Hammer, B. Bosworth, D. Stine, E. Springer, T. Johnson, Evaluation of One-Dose MycoPlasma hyopneumoniae bacterin (PneumoSTAR Myco) at 23 Weeks Post Vaccination, American Association of Swine Veterinarians (2005)

D. Nilubol, et al., The Effect of a Killed Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), etc. 102 VETERINARY MICROBIOLOGY 11-18 (2004) ("Nilubol")

S.J. Barteling & J. Vreeswijk, Developments in Foot-and-Mouth Disease Vaccines, 9 VACCINE 75-86 (Feb. 1991) ("Barteling")

J. Srinivasappa, I. Morozou, M. Gill, & H. Chu, Efficacy, Safety and Serological Cross-Reactivity of Fort Dodge Animal Health's Swine Influenza Vaccine, American Association of Swine Veterinarians (2003) ("Srinivasappa")

H. Bahnemann, Inactivation of Viral Antigens for Vaccine Preparation with Particular Reference to the Application of Binary Ethylenimine, 8 VACCINE 299-303 (1990) ("Bahnemann")

C. Charreyre, S. BESEME, L. Boeuf-Teseschi, M. Bublot, & G. Reynaud, Protection Against PCV2 Experimental Challenge in 3 Week-Old Piglets by Maternal Antibodies, Proceedings of the 17th IPVS Congress, Ames, Iowa, USA (2002) ("Charreyre")

Declaration of Dr. Phil Hayes ("Hayes Declaration")

Declaration of Sylvia D. Hall-Ellis, Ph.D.

Petition for Inter Partes Review of U.S. Patent No. 9,011,872

W.L. Mengeling, T.T. Brown, P.S. Paul, & D.E. Gutekunst, Efficacy of an Inactive Virus Vaccine for Prevention of Porcine Parvovirus-Induced Reproductive Failure¿¿40 AM. J. VET. RES. 2 (Feb. 1979) ("Mengeling")

F. Brown, Inactivation of Viruses by Aziridines, 20 VACCINE 322-327 (2002) ("Brown")

P.A. Harms, et al., Experimental Reproduction of Severe Disease in CD/CD Pigs Concurrently Infected with Type 2 Porcine Circovirus and PRRSV, 38 VET. PATHOL. 528-539 (2001) ("Harms")

K. Diehl, et al., A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and Volumes, 21 J. APPL. TOXICOL. 15-23 (2001) ("Deihl")

M.M. Hulst, D.F. Westra, G. Wensvoort, & R.J.M. Moormann, Glycoprotein E1 of Hog Cholera Virus Expressed in Insect Cells Protects Swine from Hog Cholera, 67 J. VIROLOGY 9:5435-5442 (Sept. 1993) ("Hulst")